CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will participate at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY.
新泽西普林斯顿,2024年11月26日(环球新闻)-- CytoSorbents公司(纳斯达克:CTSO),在重症监护室和心脏外科使用血液净化治疗危及生命的病症方面的领先者,今天宣布管理层将参加于2024年12月3日至5日在纽约举行的派杰投资第36届年度医疗保健会议。
Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, will participate in one-on-one investor meetings on Wednesday, December 4, 2024.
首席执行官Phillip Chan博士和首席财务官Peter J. Mariani将于2024年12月4日星期三参加一对一投资者会议。
For more information or to schedule a meeting with management, please contact your Piper Sandler representative or contact the Company's investor relations team at ir@cytosorbents.com.
有关更多信息或安排与管理层的会议,请联系您的派杰投资代表或通过ir@cytosorbents.com联系公司的投资者关系团队。
About CytoSorbents Corporation (NASDAQ: CTSO)
关于CytoSorbents公司(NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
cytosorbents公司是通过血液净化治疗重症监护病房和心脏手术中危及生命的疾病的领导者。cytosorbents的专有血液净化技术基于生物相容性、高孔隙率的聚合物珠子,能够通过孔捕获和表面吸附主动去除血液和其他体液中的毒性物质。装满这些珠子的药筒可以与医院中已存在的标准血液泵(例如,透析、ECMO、心肺机)一起使用。cytosorbents的技术应用于多种广泛的领域。具体而言,两个重要应用是:1)在心胸手术期间和之后去除血液稀释剂,以降低严重出血的风险;2)去除常见危重疾病(例如脓毒症、烧伤、创伤、肺损伤、肝衰竭、细胞因子释放综合症和胰腺炎)中的炎性因子,这些疾病可能导致大规模的炎症、器官衰竭和患者死亡。在这些疾病中,死亡风险可能极高,且有效治疗手段寥寥无几。
CytoSorbents' lead product, CytoSorb, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.
cytosorbents的主力产品CytoSorb在欧盟获得批准,并在全球76个国家销售,迄今累计使用超过25万台设备。CytoSorb最初在欧盟推出,获得CE标志,作为第一款细胞因子吸附剂。后续CE标志延伸用于临床情况下的胆红素和肌红蛋白去除,如肝病和创伤,并用于卡格瑞洛和利伐沙班去除在心胸外科手术程序中。CytoSorb还获得了FDA紧急使用授权,在美国用于成人危重病因COVID-19患者患有临危或确认的呼吸衰竭,以降低促炎细胞因子水平。CytoSorb尚未在美国获批。
In the U.S. and Canada, CytoSorbents is developing the DrugSorb-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.
在美国和加拿大,cytosorbents正在开发DrugSorb-ATR抗血栓去除系统,这是一种基于与cytosorb等效的聚合物技术的试验性器械,旨在减少因抗凝药物导致的高风险手术中的围手术期出血严重性。它已获得两项FDA突破性器械认定:一项用于去除替卡格雷和另一项用于在紧急心胸手术中去除直接口服抗凝剂(DOAC)阿哌沙班和利伐沙班。在2024年9月,公司向美国FDA提交了一份De Novo医疗器械申请,请求批准在接受抗血栓药物替卡格雷的冠状动脉旁路移植术(CABG)患者中减轻围手术期出血的严重性,该申请于2024年10月被接受进行实质性审查。2024年11月,公司获得了医疗器械单一审计计划(MDSAP)认证,并向加拿大卫生部提交了医疗器械许可证(MDL)申请。DrugSorb-ATR尚未在美国和加拿大获得批准。
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY, CytoSorb-XL, HemoDefend-RBC, HemoDefend-BGA, VetResQ, K+ontrol, DrugSorb, ContrastSorb, and others. For more information, please visit the Company's website at or follow us on Facebook and X.
公司基于这一独特的血液净化技术开发了众多市场上销售的产品和正在研发的产品,受到许多已颁发的美国和国际专利以及注册商标的保护,同时还有多项待批专利申请,包括ECOS-300CY,CytoSorb-XL,HemoDefend-RBC,HemoDefend-BGA,VetResQ,K+ontrol,DrugSorb,ContrastSorb等。欲了解更多信息,请访问公司网站或关注我们的Facebook和X。
Forward-Looking Statements
前瞻性声明
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
本新闻稿包含旨在符合1995年《私人证券诉讼改革法案》设立的豁免责任安全港的前瞻性声明。这些前瞻性声明包括但不限于关于我们计划、目标、未来目标和业务展望、陈述和主张,以及我们监管提交的结果,并非历史事实,通常通过"可能"、"应当"、"可能"、"预期"、"计划"、"预期"、"相信"、"估计"、"预测"、"潜在"、"继续"等词语来识别,尽管有些前瞻性声明是以不同方式表达的。您应该知道,本新闻稿中的前瞻性声明代表管理层目前的判断和预期,但我们的实际结果、事件和业绩可能与前瞻性声明中的内容大不相同。可能导致或有助于产生这种差异的因素包括但不限于在2024年3月14日向SEC提交的年度10-k表中讨论的风险,以及在我们的季度10-Q表中报告的风险,以及我们不时发出的面向股东的新闻稿和其他通信中报告的风险和可能影响我们业务的因素。我们提醒您不要过度依赖此类前瞻性声明。我们无需公开更新或修订任何前瞻性声明,除非根据联邦证券法的要求。
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com
美国公司联系人:
彼得·J·马里安尼,首席财务官
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com
Investor Relations Contact:
Aman Patel, CFA
ICR-Westwicke
ir@cytosorbents.com
投资者关系联系人:
阿曼·帕特尔,特许金融分析师
ICR-Westwicke
ir@cytosorbents.com